Targeting the upstream transcriptional activator of PD-L1 as an alternative strategy in melanoma therapy

Programmed cell death ligand 1 (PD-L1) interacts with programmed cell death protein-1 (PD-1) as an immune checkpoint. Reactivating the immune response by inhibiting PD-L1 using therapeutic antibodies provides substantial clinical benefits in many, though not all, melanoma patients. However, transcri...

Full description

Bibliographic Details
Main Authors: Zhu, B, Tang, L, Chen, S, Yin, C, Peng, S, Li, X, Liu, T, Liu, W, Han, C, Stawski, L, Xu, Z, Zhou, G, Chen, X, Gao, X, Goding, C, Xu, N, Cui, R, Cao, P
Format: Journal article
Published: Springer Nature 2018